Riverside sells Diatron to Stratec Biomedical

The GP stated it grew Diatron by adding clinical chemistry and reagents to its product offering, opening a US subsidiary, receiving FDA approval for several product groups, and expanding its customer base.

Riverside also completed the add-on of MetroLab for Diatron in 2008 and claims the company tripled its turnover during its ownership.

Previous funding
Riverside acquired Diatron in December 2005 via its Riverside Europe Fund III. MKB Bank provided debt for the transaction.

Company
Diatron, founded in 1989, specialises in the development, manufacture and marketing of compact haematology analysers for the human medical and veterinary markets. The company's instruments are used in 100 countries spanning five continents.

Diatron is composed of a research, development and production arm based in Budapest, and an export sales and marketing arm, based in Vienna. Its revenues were €34m in 2015. 

People
Riverside – Michael Weber (partner).
Diatron – Jim Schepp (CEO).

Advisers
Seller – Lincoln International (M&A); Allen & Overy (legal); EY (financial due diligence).

• Tweet  
• Facebook  
• LinkedIn  
• Google plus  
• Send to  

• Topics
• Exits
• CEE
• Healthcare
• Hungary
• Trade sale
• Riverside